Form 4: Amylyx Pharmaceuticals Co-CEO Exercises Stock Options
SEC Form 4 Filing
Justin B. Klee, Co-CEO of Amylyx Pharmaceuticals, exercised stock options on November 4, 2024, acquiring 63,690 shares of common stock.
Summary
- On November 4, 2024, Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals, exercised stock options.
- This transaction involved the acquisition of 63,690 shares of common stock at a price of $1.57 per share.
- Following the transaction, Klee directly owns 3,184,259 shares of Amylyx Pharmaceuticals.
- Klee also owns 36,310 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports an insider transaction. The exercise of options could be seen as a positive signal, but without further context, it's difficult to assess the overall impact.
Positives
- The exercise of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.
Stakeholder Impact
- The transaction could have a minor impact on shareholders, potentially increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 11/04/2024 | Date of the stock option exercise and acquisition of common stock. |
| 02/26/2025 | Expiration date of the stock options. |
| 11/06/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.